UBS Group Cuts Harmony Biosciences (NASDAQ:HRMY) Price Target to $36.00

Harmony Biosciences (NASDAQ:HRMY) had its price target reduced by UBS Group from $46.00 to $36.00 in a research note released on Wednesday,Benzinga reports. They currently have a neutral rating on the stock.

Several other research analysts have also recently issued reports on the company. Oppenheimer reaffirmed an “outperform” rating and set a $62.00 price objective on shares of Harmony Biosciences in a research report on Monday, November 24th. Mizuho set a $50.00 price target on Harmony Biosciences in a report on Thursday, February 19th. Truist Financial lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of Harmony Biosciences in a research report on Wednesday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Harmony Biosciences in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $42.67.

Harmony Biosciences Trading Down 1.8%

NASDAQ HRMY opened at $28.54 on Wednesday. Harmony Biosciences has a 52 week low of $25.52 and a 52 week high of $40.87. The firm has a 50 day moving average of $36.01 and a two-hundred day moving average of $34.07. The stock has a market capitalization of $1.65 billion, a PE ratio of 10.53, a price-to-earnings-growth ratio of 0.36 and a beta of 0.84. The company has a quick ratio of 3.72, a current ratio of 3.60 and a debt-to-equity ratio of 0.17.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.46). The firm had revenue of $243.78 million for the quarter, compared to analysts’ expectations of $240.04 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.Harmony Biosciences’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same period last year, the firm posted $0.85 earnings per share. As a group, research analysts expect that Harmony Biosciences will post 2.43 EPS for the current fiscal year.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $37.15, for a total value of $139,163.90. Following the completion of the transaction, the chief financial officer owned 24,521 shares in the company, valued at $910,955.15. This trade represents a 13.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 50,640 shares of company stock valued at $1,932,256. 23.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Harmony Biosciences

Several institutional investors have recently bought and sold shares of the company. Amundi raised its position in Harmony Biosciences by 115.6% during the 1st quarter. Amundi now owns 39,668 shares of the company’s stock worth $1,229,000 after buying an additional 21,266 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Harmony Biosciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after acquiring an additional 984 shares during the period. Empowered Funds LLC purchased a new position in Harmony Biosciences during the first quarter worth about $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Harmony Biosciences by 53.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock valued at $3,166,000 after purchasing an additional 33,058 shares during the period. Finally, AlphaQuest LLC boosted its holdings in Harmony Biosciences by 340.2% in the 2nd quarter. AlphaQuest LLC now owns 17,601 shares of the company’s stock valued at $556,000 after purchasing an additional 13,603 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $55 price target and published a long-range FY2030 EPS projection (which reinforces an upbeat long-term thesis), supporting upside potential despite near-term cuts. HC Wainwright research on HRMY
• Neutral Sentiment: An aggregate coverage note reported HRMY has an average analyst rating of “Moderate Buy,” indicating mixed consensus sentiment across the sell-side. This tempers the impact of individual downgrades but leaves the stock sensitive to further model changes. Average analyst rating report
• Negative Sentiment: Zacks Research downgraded HRMY from “strong-buy” to “hold,” reducing near-term buy-side conviction and likely contributing to selling pressure. Zacks downgrade
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” citing patent trial developments — a direct legal/intellectual property risk that can materially affect exclusivity and future revenue, and is a key reason for today’s weakness. Truist downgrade after patent trial developments
• Negative Sentiment: HC Wainwright also lowered near-term EPS forecasts across Q1–Q4 2026 (multiple cuts to quarterly estimates), signaling weaker near-term profitability expectations that can pressure the stock until guidance or sales trends rebound. HC Wainwright EPS revision details

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.